CU Anschutz Medical Campus

CU Anschutz Launches Novel Immunotherapy Trial for Autoimmune Encephalitis

- CU Anschutz Medical Campus initiated a clinical trial for a novel immunotherapy drug targeting autoimmune diseases, with the first patient showing promising recovery. - The trial focuses on anti-NMDA receptor encephalitis, a rare neurologic inflammation characterized by delirium, seizures, and memory loss, often triggered by tumors. - The immunotherapy aims to modulate the immune system's response, preventing it from attacking the brain, offering a new treatment avenue for this severe condition.